<DOC>
	<DOCNO>NCT02686788</DOCNO>
	<brief_summary>The purpose study assess impact TMP001 treatment patient relapsing-remitting multiple sclerosis ( RRMS ) . Therefore average total number contrast enhance lesion ( CELs ) brain MRI scan week 12 , 16 , 20 , 24 treatment TMP001 compare average total number CELs brain MRI scan week -4 baseline patient . Based promising preclinical result , investigator assume comparable effect TMP001 reduction contrast-enhancing lesion show immunomodulatory substance recent clinical study .</brief_summary>
	<brief_title>TMP001 Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Age 18 55 year Definite diagnosis RRMS ( accord revise McDonald criterion , Polman et al . 2011 , Annals Neurology 69:292302 ) At least 1 documented relapse previous year OR least 2 documented relapse previous 2 year At least one contrastenhancing lesion ( CEL ) screen MRI scan week ( 4 ) EDSS 0 5 ( inclusive ) screening ( week 4 ) Women childbearing potential ( WOCBP ) must use 2 adequate form contraception avoid pregnancy throughout trial ( double barrier method ) 8 week last dose TMP001 manner risk pregnancy minimize Written inform consent obtain prior initiation protocolrequired procedure Compliance study procedure study protocol History chronic disease immune system MS know immunodeficiency syndrome Clinically severe active infection ( e.g. , pneumonia , septicaemia ) within 1 month prior Screening . Diagnosis neuromyelitis optica , clinically isolated syndrome , secondary progressive multiple sclerosis , primary progressive multiple sclerosis History drug alcohol abuse within 2 year inclusion study Relapse corticosteroid treatment within 30 day screen ( week 4 ) Interferonbeta , glatiramer acetate , teriflunomide , dimethyl fumarate fingolimod therapy stop 3 month enrolment Immunosuppressive medication azathioprine methotrexate , Ciclosporin , cyclophosphamide , mycophenolate mofetil , mitoxantrone cladribine time Any previous therapy alemtuzumab , ocrelizumab , ofatumumab , rituximab , belimumab , natalizumab , total body irradiation , bone marrow transplantation Any investigational drug placebo within 12 week prior enrolment OR &gt; 5 halflives prior screen ( week 4 ) , whichever long Women pregnant currently breast feed Concurrent participation clinical trial History , current diagnosis , malignancy ( include previously treat skin cancer successfully treat basal squamous skin cancer evidence recurrence within 5 year ) Inability complete MRI contraindication MRI , include limited claustrophobia , presence pacemaker , cochlear implant , ferromagnetic device clip , intracranial vascular clip , insulin pump , nerve stimulators Hypersensitivity contrast agent ( Gadolinium , resp . gadopentetatedimeglumine ) Any reason discretion investigator regard safe participation patient study reason , investigator considers patient inappropriate participation study . White blood count ( WBC ) &lt; 3000 mm3 screening ( week 4 ) Lymphocytes &lt; 800 mm3 screening ( week 4 ) Exclusion criterion regard study medication : Patients know hypersensitivity study medication Patients experience asthma , urticaria , allergictype reaction take aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) Patients history peptic ulcer disease and/or gastrointestinal bleeding Chronic acute renal , hepatic metabolic disorder Patients history myocardial infarction , ischemic stroke know heart failure Patients know thrombophilia abnormal clinically significant coagulation parameter screening ( week 4 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>relapse remit</keyword>
	<keyword>nonsteroidal anti-inflammatory drug</keyword>
	<keyword>contrast enhancing lesion</keyword>
</DOC>